A ShAred deciSion-mAking model propoSAl
We propose a new and simple grade system to classify the actual complex clinical scenario of UIA management based on shared decision-making practices 5, 6 . First, we summarize a flowchart that includes the main paradigms of management of patients presenting UIA (Figure) . Second, we divide doctors' indications and patients' intentions between four pretreatment clinical settings (Table) . The doctors' indications were divided into two categories: the first is when the doctor indicates invasive treatment and the second is when the doctor indicates medical management. The patients' perspectives were divided between two groups. The first group consists of patients prone to choosing invasive treatment, and the second group consists of patients prone to choosing medical management. From the doctor indications and patient preferences mentioned above, four pretreatment settings were identified (Table) . These four settings will result in one of three possible final decisions. The final decisions are (A) an invasive treatment, (B) medical management and (C) a definitive disagreement between doctor and patient. Pretreatment settings I and IV may result in decisions A and B, respectively, whereas settings II and III may result in decision C, or A, or B as well. Patients that choose decision C may look for other expert opinions. The best management of UIA remains controversial, mainly because best scientific data, which come from randomized trials, are lacking. In a first encounter between doctor and patient presenting an UIA, both doctor and patient often face unresolved dilemmas about the treatment of UIA. The first dilemma is about conservative versus invasive treatment. If an invasive treatment is chosen, other questions emerge regarding which is the best invasive approach (surgical or endovascular). Moreover, when the endovascular treatment is indicated, there are described several strategies to achieve treatment of UIA ( Figure) . Currently, scientific data from randomized trials are not available to guide doctors and patients to solve all questions and dilemmas mentioned above.
Controversies on best management of UIA can be observed by assessing doctors' indications on UIA management. Interventional neuroradiologists and neurosurgeons usually rely on variables like patient age, operative risk factors, aneurysm size, morphology, location, growth rate, and intra-aneurysmal flow patterns to support their decisions regarding UIA management. However, substantial disagreement between doctors on management of UIA has been recently reported 8, 9, 10 , which suggests that doctors are not absolutely or uniformly sure about their beliefs on the management of UIA.
Concerning scientific attempts to solve the problem of aneurysm management, several studies have proposed probabilistic decision models to aid doctors in their choices, including decision trees and score risks 11, 12, 13, 14, 15 . A recent interesting study, proposed a mathematical score (the PHASES score) to predict the 5-year rupture risk of UIA. Constructed based on a pooled analysis of six large UIA prospective cohorts studies including 8382 patients, the PHASES risk score comprises six predictors: age, arterial hypertension, previous subarachnoid hemorrhage, aneurysm size, aneurysm location, and geographical region. The PHASES score range from 0 to 22 points and the 5-year risk of aneurysm rupture range from 0.4 to 17.8% 16 . However, studies designed to predict aneurysm rupture risk, and to guide clinical decisions, have been exhaustively criticized mainly because most of prediction models were based on data extracted of observational cohorts, which have important selection bias and, thus, do not reliably represents all patients presenting UIA 17, 18, 19, 20, 21, 22, 23 . In this context, risk prediction models are probably misleading tools to support clinical decision-making.
Shared decisions have been argued as a good practice during complex and uncertain clinical situations, wherein the best clinical management is not yet known, and its benefit has not yet been adequately proven. As the best management of UIA is unknown, shared decisions may prevent unilateral decisions by paternalistic doctors or may help doctors and patients share the hard responsibility to make a difficult decision in a context of uncertainty. In addition, compared to the paternalistic model, shared decisions may play an important role in preventing lawsuits in the setting of treatment-related complications.
Concerning the scientific value of shared decisions, the current scientific method used for clinical research is based on hypothesis verification by means of clinical experiments and the final results obtained may prove or contest and redefine the initial hypothesis 24 . Because of the subjective desires of patients and the variable indications of doctors 8, 9, 10 , we do not believe that a shared decision-making classification system, as described above, could generate specific scientific hypothesis for randomized trials. Nevertheless, whether study's results could be influenced by shared decisions before enrollment in trials is unknown, and it has to be demonstrated. Unfortunately, randomization has been reported to be difficult to achieve in the setting of UIA management 25 , and currently, most of the studies published on UIA treatment have a nonrandomized design.
On the other hand, shared decision-making may influence results of nonrandomized studies, because patients' and doctors' decisions may play an important role in achieving imbalances between groups, which are explained by the following examples. First, high-risk and older patients may be prone to deciding in favor of medical management, whereas young and healthy patients may favor invasive treatment. Second, the availability of a minimally invasive treatment may influence patients to decide against medical management and choose embolization rather than clipping. Third, doctors may indicate invasive treatment for the young and healthy patients, and the medical management for older and high-risk patients. Fourth, doctors may indicate endovascular treatment for older patients presenting large aneurysms, and indicate clipping for young and healthy patients. Therefore, a survey of the factors influencing doctors and patients on final decisions could explain the distribution of baseline variables or investigate what is the role of patients and doctors is in the increasing indications of endovascular treatment for UIA 26 (Table) . The practice of shared decision-making in daily clinical practice should make doctors and patients aware that they have been making clinical choices in obscure scientific environments. Therefore, such a practice may stimulate doctors and patients to participate in clinical trials.
problemS of ShAred deciSion-mAking in the context of uiA
The principle of autonomy is a central issue in shared decisions practice. However, autonomy presupposes competency, rational desires, and above all, reliable knowledge 27 . From that point of view, valid scientific knowledge is essential for a true shared decision-making practice, which is the problem of UIA care, where scientific data is scarce, incomplete and unreliable. Therefore, the lack of valid information about UIA management may increase the subjectivity and the scientific imprecision of shared decision-making.
Another fundamental issue about shared decisions for UIA management is to block scientific data acquisition. It is possible that shared decisions influence doctors to feel ethically comfortable during their daily clinical decisions on UIA management. If doctors feel comfortable in their decisions, research on UIA would be compromised because it could reduce doctors' interest in enrolling patients in trials.
finAl remArkS
Shared decision-making is considered an ethical way to deal with patients in daily clinical care. However, in the context of UIA care, shared decision-making practice should not be a justification to doctors feel ethically comfortable about their decisions. We believe that a scientific value of shared decision-making practice may be to arouse doctors and patients about the lack of reliable data on UIA management, and thus to encourage all to participate in clinical trials. 
